Clinical Trial Update: Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating Revumenib in colorectal cancer and other solid tumors has completed Phase 1 and Phase 2. The sponsor is Syndax Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Revumenib (revumenib)

Snippet

Sponsor: Syndax Pharmaceuticals | Conditions: Colorectal Cancer, Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED